All In Biotech

Drug Trial Radar · NCT07923357

A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus

A Phase 2, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics Characteristics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus Inadequate Glycemic Control

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 364 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

364

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Nov 30, 2027

Study completion Nov 30, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind (with open-lable semaglutide 1.0 mg, active comparator), placebo-and active-controlled, parallel-group Phase 2 clinical trial aimed at evaluating the efficacy, safety and pharmacokinetic (PK) characteristics of SAL0150 tablets in subjects with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control after diet and exercise alone or after diet and exercise combined with stable-dose metformin monotherapy.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)
  • Type 2 Diabetes
  • T2DM

Interventions

  • SAL0150 dose 1Drug

    SAL0150 tablets, use as specified in the protocol

  • SAL0150 dose 2Drug

    SAL0150 tablets,use as specified in the protocol

  • SAL0150 dose 2Drug

    SAL0150 tablets, use as specified in the protocol

  • SAL0150 dose 3Drug

    SAL0150 tablets, use as specified in the protocol

  • SAL0150 dose 3Drug

    SAL0150 tablets, use as specified in the protocol

  • PlaceboDrug

    Placebo

  • Semaglutide inject 1.0 mgDrug

    Semaglutide inject, 1.0 mg once weekly, 15 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1cTime frame: Change From Baseline in HbA1c at Week 16(Baseline, Week 16)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.